Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Commodities
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
News Focus
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA and Income (click to learn more)
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Symbility Solutions, Inc.
ATBEF
Technology
Software - Infrastructure
"Symbility Solutions Inc develops and markets Software-as-a-Service technology designed to improve effectiveness and reduce costs of administration of claims in both the employee benefits and property and casualty insurance markets."
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (OTCPK:ATBEF)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
7
8
Next
(655)
•••
TimeBuilder
X
View Profile
View Bullboard History
Post by
TimeBuilder
on Nov 16, 2018 2:23pm
Finally All Sold @ .61
It has been a GREAT ride ...sad to see this one go....Time to move on ...GLTAll those still hang on....Regards, TimeBuilder
(655)
•••
TimeBuilder
X
View Profile
View Bullboard History
Comment by
TimeBuilder
on Nov 09, 2018 4:15pm
RE:RE:SOLD to CLGX (NYSE)
Sold >>>> copy of NR....we .DO NOT expect a HIGHER offer for SY.T GLTA. PS: But we will hang on for a while long to see what happens before year end.. The
...more
Indiva Reports Fiscal Year 2023 Results Including Record Positive EBITDA
posted Apr 25, 2024 9:00am by
Indiva Ltd
-
|
“Net Income was just shy of break-even in Q4, which is a testament to the popularity of our products, our industry leading low-cost production platform, and our focus on cost control. Our core brands, namely Pearls by Grön, No Future, Bhang Chocolate and Indiva Blips continue to gain market share in Canada, as Indiva continues to hold the #1 market share position in edibles nationally," said ...read more
(66)
•••
campst
X
View Profile
View Bullboard History
Comment by
campst
on Oct 31, 2018 9:14am
RE:Thoughts?
I think you should be buying.
(655)
•••
TimeBuilder
X
View Profile
View Bullboard History
Comment by
TimeBuilder
on Oct 26, 2018 3:09pm
RE:SOLD to CLGX (NYSE)
Is there a small chance of a better offer above .615 per share ?
(29)
•••
Vikingstock
X
View Profile
View Bullboard History
Post by
Vikingstock
on Oct 23, 2018 7:09pm
Corelogic - SY Purchase
Was just a matter of time. Would have liked .65 or so but all good. Cleaned house, time to move on..
(655)
•••
TimeBuilder
X
View Profile
View Bullboard History
Comment by
TimeBuilder
on Oct 23, 2018 12:14pm
RE:SOLD to CLGX (NYSE)
FYI: We expected a little more after the past 52 week high @ .57 BUT the .615 is still a GREAT return from our past purchases in Jan 2016 and original buy in under AUT.V in April
...more
(655)
•••
TimeBuilder
X
View Profile
View Bullboard History
Comment by
TimeBuilder
on Oct 23, 2018 12:01pm
RE:Still time to look at Symbility
===ALSO a SPAMMER=====GOOD BYE=====
(655)
•••
TimeBuilder
X
View Profile
View Bullboard History
Comment by
TimeBuilder
on Oct 23, 2018 11:58am
RE:RE:Rusoro Mining (RML) 1.28 BILLION Settlement Signed!!!
====SPAMMER'S + Friend! ====GOOD BYE====
(655)
•••
TimeBuilder
X
View Profile
View Bullboard History
Comment by
TimeBuilder
on Oct 23, 2018 11:53am
RE:Rusoro Mining (RML) 1.28 BILLION Settlement Signed!!!
=====SPAMMER=======THANK YOU====GOOD BYE
(655)
•••
TimeBuilder
X
View Profile
View Bullboard History
Post by
TimeBuilder
on Oct 23, 2018 8:50am
SOLD to CLGX (NYSE)
Today's NR = Copy for your viewing PLEASURE CoreLogic to Acquire Symbility Solutions Canada Newswire - Mon Oct 22, 5:05PM CDT TORONTO, Oct. 22, 2018 /CNW/ - Symbility
...more
(655)
•••
TimeBuilder
X
View Profile
View Bullboard History
Post by
TimeBuilder
on Aug 07, 2018 11:03am
Today's News Release
For your viewing PLEASURE ..... ENJOY Symbility Helps Aviva Enhance Policyholders' Claim and Risk Management Experience CNW Group - Tue Aug 7, 5:00AM CDT
...more
(29)
•••
Vikingstock
X
View Profile
View Bullboard History
Comment by
Vikingstock
on Jun 08, 2018 5:50pm
RE:RE:RE:RE:Finally
NIce steady climb since March. With more deals on the way, good results, the stock will continue to move up. Could there be a buyout on the Way?
(655)
•••
TimeBuilder
X
View Profile
View Bullboard History
Post by
TimeBuilder
on Jun 08, 2018 1:30pm
$ .57
:>O
(2)
•••
Ranger56
X
View Profile
View Bullboard History
Comment by
Ranger56
on Jun 07, 2018 2:44pm
RE: ANOTHER 52 week HIGH @ $ .55
This sleepy little stock is breaking out and hardly anyone knows about it or interested. I get it...took a long time to become a profitable company. It is now cash flow positive, growing revenues at
...more
(655)
•••
TimeBuilder
X
View Profile
View Bullboard History
Post by
TimeBuilder
on Jun 07, 2018 1:40pm
ANOTHER 52 week HIGH @ $ .55
:>)
Prev
1
2
3
4
5
6
7
8
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Discover a Green Resources Stock Scoring Record Quarterly Growth
Two New Contracts Awarded Covering Five Onshore Fields Producing 3,000 bbl/d of Oil
Stage Set for Creation of a Leading Intermediate Gold Producer
Centurion Identifies High Quality Gold Target-Casa Berardi West Project; Acquires Additional Claims
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study